Methodology for Identifying Acquisition Targets in Biotech

This case study outlines the methodology employed by a biotech company specializing in oncology therapies to identify high-potential acquisition targets in the antibody space. The objective was to acquire a late-stage asset that would enhance the existing pipeline. The approach involved a systematic, multi-step filtering process leveraging Intelligencia AI’s data and analytics capabilities. Initial landscape mapping identified companies with ongoing programs in specific antibody technology areas. Exclusion criteria were applied to focus on agile, innovation-driven biotech firms, excluding Big Pharma and companies outside the U.S. Further filtering was based on the Probability of Technical and Regulatory Success (PTRS) assessments, narrowing the selection to companies with high-ranking programs. The final shortlist included four acquisition candidates, selected for their strong program performance and alignment with the client’s strategic goals. The AI-driven process facilitated timely and confident decision-making in a competitive market.